Changes in the NSE and S100B Levels in Plasma Following Treatment with Peripheral Neuropathy-Inducing Chemo Drugs
Abstract
Peripheral Neuropathy (PN) is a common chemotherapy-induced side effect that impacts 50% of all patients who receive chemotherapy. Treatment with Bortezomib (BTZ), Cisplatin (CIS), and Vincristine (VIN) has been established as the most common triggers of Chemotherapy-Induced Peripheral Neuropathy (CIPN) among cancer patients. Therefore, it was hypothesized that identifying diagnostic/prognostic biomarkers that can accurately predict the onset or progression of CIPN would help to determine the eligibility of the above-mentioned drugs for chemotherapy use and also would help to proactively prepare the patients for protective care. Therefore, our initial goal was to elucidate the molecular mechanisms underlying the onset and progression of CIPN that would first allow for the identification of suitable biomarkers, which can be used for monitoring CIPN before or during chemotherapy with BTZ, CIS, and VIN. We conducted an in-vivo study to determine the CIPN-related biomarkers using Sprague-Dawley rats. We used plasma from chemo-drug-treated rats to check the NSE and S100B levels using the ELISA method. Our preliminary study showed an elevation in NSE and S100B levels in the plasma of the experimental rats that showed a steady increase following 8 weeks of treatment with the PN-inducing chemo drugs. We anticipate that this study will enrich our understanding of how chemotherapy drugs induce CIPN in cancer patients and further guide us to validate S100B and NSE as reliable biomarkers.
(This project was supported by the PFRDG grant of Nova Southeastern University, Ft. Lauderdale Florida, and the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
Faculty Sponsors
Dr. Umamaheswari Natarajan, Dr. Appu Rathinavelu, Dr. Eben Gering, Dr. Julie Torruellas Garcia
Project Type
Event
Location
Alvin Sherman Library
Start Date
4-3-2024 12:30 PM
End Date
4-4-2024 1:30 PM
Changes in the NSE and S100B Levels in Plasma Following Treatment with Peripheral Neuropathy-Inducing Chemo Drugs
Alvin Sherman Library
Peripheral Neuropathy (PN) is a common chemotherapy-induced side effect that impacts 50% of all patients who receive chemotherapy. Treatment with Bortezomib (BTZ), Cisplatin (CIS), and Vincristine (VIN) has been established as the most common triggers of Chemotherapy-Induced Peripheral Neuropathy (CIPN) among cancer patients. Therefore, it was hypothesized that identifying diagnostic/prognostic biomarkers that can accurately predict the onset or progression of CIPN would help to determine the eligibility of the above-mentioned drugs for chemotherapy use and also would help to proactively prepare the patients for protective care. Therefore, our initial goal was to elucidate the molecular mechanisms underlying the onset and progression of CIPN that would first allow for the identification of suitable biomarkers, which can be used for monitoring CIPN before or during chemotherapy with BTZ, CIS, and VIN. We conducted an in-vivo study to determine the CIPN-related biomarkers using Sprague-Dawley rats. We used plasma from chemo-drug-treated rats to check the NSE and S100B levels using the ELISA method. Our preliminary study showed an elevation in NSE and S100B levels in the plasma of the experimental rats that showed a steady increase following 8 weeks of treatment with the PN-inducing chemo drugs. We anticipate that this study will enrich our understanding of how chemotherapy drugs induce CIPN in cancer patients and further guide us to validate S100B and NSE as reliable biomarkers.
(This project was supported by the PFRDG grant of Nova Southeastern University, Ft. Lauderdale Florida, and the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
